First Wave To Merge With ImmunogenX With Focus On Celiac Disease
Executive Summary
Troubled by recent clinical disappointments, First Wave will combine with ImmunogenX to focus on that company’s Phase III-ready enzyme replacement therapy for celiac disease. A deep-pocketed partner waits in the wings.